Prognostic and Diagnostic Utility of Interleukin-6 in Pediatric Pulmonary Arterial Hypertension - A case control study

Résumé

Abstract Background: Pulmonary arterial hypertension (PAH) in pediatrics is a progressive disease with significant vascular remodeling, right sided heart failure, and death if left untreated. Elevated interleukin-6 (IL-6) level in PAH patients is taken as an independent predictor of adverse outcome including mortality. The aim of this study was to investigate and compare serum levels of IL-6 in children with PAH and healthy matched controls, and correlate between between IL-6 and degree of PAH, as well as mortality. Method: IL-6 was measured by ELISA in serum samples in 40 children with PAH (age 1-12 years) and 40 age and sex matched healthy controls. Results: There was statistically significant increase in IL-6 level among PAH cases compared with the controls (1.85 ng/L vs 1.30 ng/L, p-value =0.004). IL-6 at cut off point 1.45ng/L significantly predict pulmonary hypertension in children, (AUC=0.685, 75% sensitivity, and 65% specificity with p=0.002). There was no statistically significant association between IL-6 level and degree of PAH (p=0.218). There was no statistically significant association between IL-6 level and mortality (p=0.662). Conclusion: IL-6 significantly predict PAH in pediatrics but there is no association between IL-6 level and degree of PAH or mortality. IL-6 may provide a less costly, and less invasive method for disease detection.

Citer ce document

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0